Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Pertuzumab (Perjeta) - In combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) at high risk of recurrence.

patients were allowed to receive concomitant radiotherapy and/or adjuvant hormone therapy, if indicated, according to standard therapy. 2, 3 The primary outcome was invasive disease-free survival (IDFS), measured in the intention to treat population and defined as the time from randomisation until the date of the first occurrence of one of the following events: ? ipsilateral invasive breast tumour recurrence (an invasive breast cancer involving the same breast parenchyma as the original primary lesion (...) receptor has been identified as an important target for the treatment of breast cancer due to its involvement in regulating cell growth, survival, and differentiation. Amplification and/or overexpression of HER2 occurs in around 15% to 20% of breast cancers and is associated with increased tumour aggressiveness, higher rates of recurrence, and increased mortality. 3 The submitting company has requested that SMC considers pertuzumab when positioned for use in patients with lymph node-positive disease

2020 Scottish Medicines Consortium

2. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT Full Text available with Trip Pro

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website (...) search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This trial showed that in patients with HER2-positive early breast cancer, 6 months' adjuvant trastuzumab was non-inferior to 12 months', with less cardiac toxicity and fewer severe adverse events. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , & . Helena Earl 1, 2, 3, * , Louise Hiller 4 , Anne-Laure Vallier 5 , Shrushma Loi 4

2020 NIHR HTA programme

3. Alpelisib (Piqray) - metastatic breast cancer

Alpelisib (Piqray) - metastatic breast cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

4. Trastuzumab for treating HER2-positive breast and gastric cancers

Trastuzumab for treating HER2-positive breast and gastric cancers 1 Driving better decision-making in healthcare Trastuzumab for treating HER2-positive breast and gastric cancers Technology Guidance from the MOH Drug Advisory Committee Published on 1 September 2020 Guidance recommendations The Ministry of Health’s Drug Advisory Committee has recommended: ? Trastuzumab biosimilar (Ogivri) 440 mg powder for IV injection for treating: ? HER2-positive early or metastatic breast cancer, or ? HER2 (...) breast and gastric cancers. The Agency for Care Effectiveness conducted the evaluation in consultation with clinical experts from the public healthcare institutions. Published clinical and economic evidence for Herzuma and Ogivri was considered in line with their registered indications. The evidence was used to inform the Committee’s deliberations around four core decision-making criteria: ? Clinical need of patients and nature of the condition; ? Clinical effectiveness and safety of the technology

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

5. Effectiveness of four types of bandages and kinesio-tape for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial

Effectiveness of four types of bandages and kinesio-tape for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial Effectiveness of four types of bandages and kinesio-tape for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) -tape for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial , , , , , Affiliations Expand Affiliations 1 Physiotherapy Department, Physiotherapy in Women's Health Research Group, Faculty of Physiotherapy, University of Alcalá, Alcalá de Henares, Madrid, Spain. 2 Faculty of Physiotherapy and Nursing, University of Castilla-La Mancha, Toledo, Spain. PMID: 32580577 DOI: Item in Clipboard Effectiveness of four types of bandages and kinesio-tape for treating breast

2020 EvidenceUpdates

6. Alpelisib (Piqray) - postmenopausal women and men with breast cancer

, alpelisib, works by blocking the activity of the abnormal PI3K, thereby reducing the growth and spread of the cancer. Piqray (alpelisib) EMA/298596/2020 Page 2/2 What benefits of Piqray have been shown in studies? A main study involved 340 patients with advanced breast cancer with a PIK3CA mutation in whom hormone treatment had not worked or the cancer had come back. Patients treated with Piqray in combination with fulvestrant lived on average for 11 months without their disease getting worse compared (...) are greater than its risks and it can be authorised for use in the EU. Piqray used with fulvestrant increased the time before the disease got worse in patients with HR-positive and HER2-negative breast cancer that is advanced or has spread. In terms of the medicine’s side effects, the main concern is high blood sugar levels which may lead to diabetes and gut problems but the Agency has recommended measures to manage this. What measures are being taken to ensure the safe and effective use of Piqray

2020 European Medicines Agency - EPARs

7. Trastuzumab (Zercepac) - breast cancer, gastric cancer

of Zercepac and why it is authorised in the EU What is Zercepac and what is it used for? Zercepac is a cancer medicine used to treat the following conditions: • early breast cancer (when the cancer has spread within the breast or to the lymph nodes [‘glands’] under the arm but not to other parts of the body) after surgery, chemotherapy (medicines to treat cancer), and radiotherapy (treatment with radiation) if applicable. It can also be used earlier in treatment, in combination with chemotherapy (...) a week or once every 3 weeks for breast cancer, and once every 3 weeks for gastric cancer. For early breast cancer, treatment is given for a year or until the disease comes back, and for metastatic breast or gastric cancer, treatment is continued for as long as it remains effective. The dose depends on the patient’s body weight, on the condition being treated and on whether Zercepac is given every week or every 3 weeks. The infusion may cause allergic reactions, so the patient should be monitored

2020 European Medicines Agency - EPARs

8. Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer – Update

Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer – Update Estrogen and Progesterone Receptor… | College of American Pathologists Group CAP_logo_rgb[1] User Toggle Navigation Menu Search Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update Background An expert panel was convened (...) to evaluate evidence in an update and reaffirmation of the 2010 “ASCO/CAP Guideline Recommendations for Immunohistochemical (IHC) Testing of Estrogen and Progesterone Receptors (ER/PgR) in Breast Cancer.” Notably the “ ” differences impact pathologists and patients, including: A new recommendation for laboratories to establish a specific standard operating procedure to ensure the validity of low positive (1-10%) or negative (0 or < 1%) interpretations and results. Correlation of ER staining

2020 College of American Pathologists

9. Neratinib (Nerlynx) - breast cancer

progression at the end of the study. A 5- year sensitivity analysis was conducted to assess durability of the treatment effect on iDFS and the impact on overall survival. Invasive disease was defined as invasive ipsilateral tumour recurrence, invasive contralateral breast cancer, local or regional invasive recurrence, distant recurrence or death from any cause. A subgroup of patients with HR-positive disease who had completed trastuzumab within 1 year of randomisation represented the licensed population (...) within NHSScotland. Indication under review: for the extended adjuvant treatment of adult patients with early- stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. In the relevant subgroup of a phase III study neratinib, given less than one year after adjuvant trastuzumab-based therapy, improved invasive disease-free survival in patients with early-stage hormone receptor positive HER2-overexpressed

2020 Scottish Medicines Consortium

10. PD-L1 (Programmed Death Ligand 1) immunohistochemistry (IHC) testing for access to atezolizumab as first line therapy for patients with locally advanced or metastatic triple-negative breast cancer (TNBC)

breast cancer, and there is likely no requirement for most patients to undergo any additional procedures associated with the collection of tumour tissue in order to perform PD-L1 IHC testing. For those with recurrent disease, PD-L1 IHC testing could be performed on archival tumour tissue. However, the Commentary stated that PD-L1 status will differ between the primary tumour and metastases for some patients. Thus, PD-L1 IHC testing should be conducted using new 12 biopsies or surgical tumour samples (...) immune cells (IC) to determine eligibility for treatment with atezolizumab plus a taxane in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC); and • Pharmaceutical Benefits Scheme (PBS) [Authority Required] listing for treatment with atezolizumab plus a taxane for the treatment of patients with unresectable locally advanced or metastatic TNBC who have evidence of PD-L1 expression on IC covering =1% of tumour area. 2. MSAC’s advice to the Minister After

2020 Medical Services Advisory Committee

11. Breast cancer: NCCP guidance for Medical Professionals on the management of patients undergoing Breast Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) outbreak

Breast cancer: NCCP guidance for Medical Professionals on the management of patients undergoing Breast Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) outbreak Version: 1 Department: NCCP Radiation Oncology Working Group Last updated: 01/04/2020 Code: RO_COVID19_1 Date for revision: 15/04/2020 Page 1 of 3 NCCP advice for Medical Professionals on the management of patients undergoing Breast Cancer Radiotherapy in response to the current novel coronavirus (COVID-19 (...) ? DoH Coronavirus (COVID-19) - https://www.gov.ie/en/campaigns/c36c85-covid-19- coronavirus/ ? Ireland’s National Action Plan in response to COVID-19 (Coronavirus) - https://www.gov.ie/en/campaigns/c36c85-covid-19-coronavirus/ 2 Purpose The purpose of this guidance document is to provide guidance to medical professionals on the management of patients undergoing Breast Cancer Radiotherapy during the COVID-19 pandemic. Version: 1 Department: NCCP Radiation Oncology Working Group Last updated: 01/04

2020 Health Service Executive (Ireland) - Clinical Guidelines

12. Interventions for Breast Cancer-Related Lymphedema: Clinical Practice Guideline From the Academy of Oncologic Physical Therapy of APTA Full Text available with Trip Pro

Interventions for Breast Cancer-Related Lymphedema: Clinical Practice Guideline From the Academy of Oncologic Physical Therapy of APTA Interventions for Breast Cancer-Related Lymphedema: Clinical Practice Guideline From the Academy of Oncologic Physical Therapy of APTA - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) ? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Phys Ther Actions . 2020 Jul 19;100(7):1163-1179. doi: 10.1093/ptj/pzaa087. Interventions for Breast Cancer-Related Lymphedema: Clinical Practice Guideline From

2020 EvidenceUpdates

13. Biomarker-based tests to support the decision for or against adjuvant systemic chemotherapy in primary breast cancer - state of knowledge

of rapid report D19-01 Version 1.1 Biomarkers in breast cancer 26 February 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - This report was prepared without the involvement of external experts. IQWiG employees ? Martina Markes ? Katrin Dreck ? Daniel Fleer ? Elke Hausner ? Fabian Lotz Keywords: Tumour Markers – Biological, Breast Neoplasms, Systematic Review Extract of rapid report D19-01 Version 1.1 Biomarkers in breast cancer 26 February 2020 Institute for Quality (...) for or against adjuvant systemic chemotherapy compared with a biomarker-independent decision strategy ? in patients with primary hormone receptor-positive, HER2-negative breast cancer and 0 to 3 affected lymph nodes taking into account the following aspects: ? the biomarker-based tests uPa/PAI-1 (Femtelle), Oncotype DX, EndoPredict / EPclin, MammaPrint, Breast Cancer Index, Prosigna, and the IHC4 test, ? the outcomes of overall survival, disease-free survival and recurrence-free survival, each over a period

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

14. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

, UK. 14 Gustave Roussy, Université Paris Saclay, INSERM, Villejuif, France. PMID: 32353342 DOI: Item in Clipboard Full-text links Cite Abstract Background: Patients with HER2-positive breast cancer who have received two or more previous therapies for advanced disease have few effective treatment options. The monarcHER trial aimed to compare the efficacy of abemaciclib plus trastuzumab with or without fulvestrant with standard-of-care chemotherapy of physician's choice plus trastuzumab in women (...) with advanced breast cancer. Methods: This phase 2, three-group, open-label trial was done across 75 hospitals, clinics, and medical centres in 14 countries. Eligible patients were women aged 18 years or older, who had hormone receptor-positive, HER2-positive advanced breast cancer with unresectable, locally advanced, recurrent or metastatic disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and who had previously received at least two HER2-targeted therapies for advanced disease

2020 EvidenceUpdates

15. Olaparib (breast cancer) - Addendum to Commission A19-57

Olaparib (breast cancer) - Addendum to Commission A19-57 1 Translation of addendum A19-97 Olaparib (Mammakarzinom) – Addendum zum Auftrag A19-97 (Version 1.0; Status: 12 December 2019). Please note: This translation is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 12 December 2019 1.0 Commission: A19-97 Version: Status: IQWiG Reports – Commission No. A19-97 Olaparib (breast cancer (...) ) – Addendum to Commission A19-57 1 Addendum A19-97 Version 1.0 Olaparib – Addendum to Commission A19-57 12 December 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Olaparib (breast cancer) – Addendum to Commission A19-57 Commissioning agency Federal Joint Committee Commission awarded on 26 November 2019 Internal Commission No. A19-97 Address of publisher Institut für Qualität und

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

16. Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

with the appropriate comparator therapy (ACT) for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in adult patients whose tumours have Programmed Cell Death-Ligand 1 (PD-L1) expression = 1% and who have not received prior chemotherapy for the treatment of their metastatic disease. The research question for the benefit assessment presented in Table 2 resulted from the ACT specified by the G-BA. Table 2: Research question of the benefit assessment of atezolizumab (...) Neoplasms, Benefit Assessment, NCT02425891 Extract of dossier assessment A19-81 Version 1.0 Atezolizumab (breast cancer) 20 December 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research question 4 2.3 Information retrieval and study pool 3 2.4 Results on added benefit 4 2.5 Probability and extent of added benefit 4 2.6 List of included

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

17. Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer

1 Recommendations Recommendations 1.1 Atezolizumab with nab-paclitaxel is recommended, within its marketing authorisation, for treating triple-negative, unresectable, locally advanced or metastatic breast cancer in adults whose tumours express PD-L1 at a level of 1% or more and who have not had previous chemotherapy for metastatic disease. It is recommended only if the company provides atezolizumab according to the commercial arrangement. Why the committee made these recommendations Why (...) Atezolizumab (T ecentriq, Roche) 'in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression = 1% and who have not received prior chemotherapy for metastatic disease' . Dosage in the marketing authorisation Dosage in the marketing authorisation 2.2 The dosage schedule is available in the summary of product characteristics. Price Price 2.3 The list price

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

18. Fluoroestrdiol F18 (Cerianna) - Diagnostic imaging agent for certain patients with breast cancer

Fluoroestrdiol F18 (Cerianna) - Diagnostic imaging agent for certain patients with breast cancer Drug Approval Package: CERIANNA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: CERIANNA Company: Zionexa-US Corporation Application Number: 212155 Approval Date: 05/20/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2020 FDA - Drug Approval Package

19. Trastuzumab (Kanjinti) - breast cancer

Trastuzumab (Kanjinti) - breast cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

20. COVID-19 Pandemic Breast Cancer Consortium’s Considerations for Re-Entry

Randy E. Stevens Katharine A. Yao American Society of Breast Surgeons Susan K. Boolbol Jill R. Dietz* Barbara L. Smith Michelle C. Specht Shawna C. Willey American Society for Clinical Oncology Miguel Martin* National Comprehensive Cancer Network Benjamin O. Anderson Harold J. Burstein William J. Gradishar Steven J. Isakoff* Janice A. Lyons* Meena S. Moran Society of Surgical Oncology Mehra Golshan* Eleftherios P. Mamounas 2 INTRODUCTION Coronavirus Disease-2019 (COVID-19) is the most widespread (...) hospitalized Chinese patients who underwent surgery for breast and thyroid cancer while testing positive for COVID- 19 infection experienced no mortality, had fewer critical symptoms, and did not require mechanical ventilation. 3 In contrast, a smaller series of 34 infected patients undergoing a variety of elective surgeries reported an increase in intensive care unit admissions and an increased mortality rate of 20.5%. 4 The study suggested that “surgery may accelerate and exacerbate disease progression

2020 American College of Surgeons